Breaking News

Lonza Launches Design2Optimize for Faster Small Molecule API Development

New model-based platform is designed to accelerate process development of active pharmaceutical ingredients.

Author Image

By: Charlie Sternberg

Associate Editor

Lonza, a contract development and manufacturing organization (CDMO), has launched its new Design2Optimize platform to enhance process development and manufacturing of small molecule APIs. The platform is based on an optimized design of experiments (DoE), which is a statistical method for enhancing process and reaction conditions. Aiming to drastically shorten the development timeline for small molecule APIs, the Design2Optimize platform employs a proprietary model-based approach that guides e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters